These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 8780817

  • 1. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [Abstract] [Full Text] [Related]

  • 2. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
    Gatell JM, Leal M, Mallolas J, Vidal C, Pumarola T, Parra R, Padró S, Caruz A, Falgueras T, Rey C, Sánchez-Quijano A, Torres Y, Lissen E, Jiménez de Anta MT, Soriano E.
    Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
    [Abstract] [Full Text] [Related]

  • 3. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P.
    AIDS Res Hum Retroviruses; 1998 Dec 20; 14(18):1653-9. PubMed ID: 9870319
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.
    Pediatr Infect Dis J; 2005 Jun 20; 24(6):503-9. PubMed ID: 15933559
    [Abstract] [Full Text] [Related]

  • 5. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S, La Seta Catamancio S, Sheridan F, Parker D.
    J Clin Virol; 2000 Dec 20; 19(3):135-42. PubMed ID: 11090748
    [Abstract] [Full Text] [Related]

  • 6. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB, Ran LJ, de Jong MD, Bakker M, van Leeuwen R, Notermans DW, Loeliger AE, de Wolf F, Danner SA, Reiss P, Boucher CA, Lange JM, Schuitemaker H.
    J Clin Invest; 1997 Nov 01; 100(9):2325-32. PubMed ID: 9410911
    [Abstract] [Full Text] [Related]

  • 7. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
    Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S.
    J Virol; 1995 Jun 01; 69(6):3510-6. PubMed ID: 7745698
    [Abstract] [Full Text] [Related]

  • 8. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P.
    AIDS; 2003 Sep 05; 17(13):1889-96. PubMed ID: 12960821
    [Abstract] [Full Text] [Related]

  • 9. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr 01; 8(4):330-4. PubMed ID: 7533640
    [Abstract] [Full Text] [Related]

  • 10. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.
    J Pediatr; 1998 Oct 01; 133(4):500-8. PubMed ID: 9787687
    [Abstract] [Full Text] [Related]

  • 11. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 01; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 12. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC.
    Ann Intern Med; 1994 Aug 15; 121(4):263-8. PubMed ID: 7518658
    [Abstract] [Full Text] [Related]

  • 13. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
    Lafeuillade A, Tamalet C, Poggi C, Pellegrino P, Tourres C, Izopet J.
    AIDS; 1997 Jan 15; 11(1):67-72. PubMed ID: 9110077
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.
    AIDS; 1998 Jun 18; 12(9):1015-20. PubMed ID: 9662197
    [Abstract] [Full Text] [Related]

  • 15. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M.
    Eur J Clin Microbiol Infect Dis; 1999 Apr 18; 18(4):274-82. PubMed ID: 10385016
    [Abstract] [Full Text] [Related]

  • 16. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
    Delta Coordinating Committee.
    HIV Med; 2001 Jul 18; 2(3):181-8. PubMed ID: 11737399
    [Abstract] [Full Text] [Related]

  • 17. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.
    Zazzi M, Catucci M, De Milito A, Romano L, Venturi G, Almi P, Gonnelli A, Rubino M, Valensin PE.
    Infection; 1996 Jul 18; 24(6):419-25. PubMed ID: 9007588
    [Abstract] [Full Text] [Related]

  • 18. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
    Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC.
    J Infect Dis; 1995 Dec 18; 172(6):1480-5. PubMed ID: 7594706
    [Abstract] [Full Text] [Related]

  • 19. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

  • 20. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
    Raskino C, Pearson DA, Baker CJ, Lifschitz MH, O'Donnell K, Mintz M, Nozyce M, Brouwers P, McKinney RE, Jimenez E, Englund JA.
    Pediatrics; 1999 Sep 28; 104(3):e32. PubMed ID: 10469815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.